Stubborn Tregs limit T-cell therapy.
In this issue of Blood, Baba and colleagues characterize a residual pool ofCD4+CD25+Foxp3+ regulatory T cells (Tregs) surviving a nonmyeloablative conditioning regimen that undergo robust homeostatic expansion to limit the full potential of adoptive T-cell therapy (ACT) for the treatment of cancer.